Piramal Pharma Solutions et NP2 vont conclure la phase de développement du cyclophosphamide le mois prochain
Piramal et NP2 devraient conclure au mois d'octobre la phase de développement du cyclophosphamide, un médicament générique contre le cancer. Les activités de développement et de fabrication sont entreprises dans l'usine de Piramal dédiée aux produits injectables stériles, située à...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Roofing Expert Jesse Curry Explains Storm Damage, Roof Leaks, Missing Shingles, Damaged Flashing, and Water Stains in HelloNation
- Parkway Electric & Communications Transitions to 100% Employee Ownership
- Loan Trading Platform ORSNN Names New Leaders
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →